Slide 1: The New Way to CDMO: Q3'25 Earnings Update
THE NEW WAY TO CDMO earnings Q3’25 update OneSource Specialty Pharma Ltd | January 29, 2025
Slide 2: Safe harbor
Safe harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 3: Quarterly Highlights Q3'25
Quarterly Highlights Q3’25 2
Slide 4: A stellar debut in its first quarter as an independent platform
A stellar debut in its first quarter as an independent platform: Strong Q3 results and significant new business wins across modalities have set the stage for continued growth and profitability ( Q3’25 Key Financial Highlights ) We're off to a promising start as an independent platform. Our strong Q3
Slide 5: Strong Q3 Performance with normalized PAT of ₹898 million
Strong Q3 Performance with normalized PAT of ₹898 million Particulars (In ₹ million) Reported Normalized Remarks EBITDA 1,432 1,432 • EBITDA margins at 36% Other income 54 54 • Interest income, Forex gain Finance cost - Continued debt (232) (232) • Recurring cost of ₹232m continuing debt Finance cos
Slide 6: Delivering continued upward trajectory
Delivering continued upward trajectory: Onesource continues building on its successful project delivery track record and a strong pipeline of ongoing projects 60+ Global customers 54 78 million 20 GLP-1 customers Successful regulatory, customer audits in last 2 years Industry leading DDC capacity (4
Slide 7: Meeting the FY25 targets
Meeting the FY25 targets : On track for a strong finish to FY25, laying the groundwork for continued and accelerated growth in the future Particulars FY25 Outlook($m) FY25 Outlook(₹m) Status o On Sep 26, 2024, Onesource updated an investor presentation via the Strides website: [Link] Revenues $160-$
Slide 8: Investing into the future: Capex of $100m over 4 years
Investing into the future: Capex of $100m over 4 years to build capacities and unparalleled CDMO capabilities Capacity FY25 FY26 FY27 FY28 Cartridges 40 100 140 220 (Million units) Pre-filled syringe 38 38 38 38 (Million units) 2.4 billion annual capacity is available as part of the transition servi
Slide 9: Outlook: Targeted Key Metrics
Outlook: Onesource creation is now complete, and we're unlocking our full potential to drive superior financial performance and deliver exceptional value to our stakeholders ( Targeted Key Metrics ) H2’25E 3–4-year Key metrics Annualized2 outlook o Capital Investments secured: Adequately funded to f
Slide 10: About OneSource
about nesource
Slide 11: Our business at a glance
India’s first Specialty Pharma CDMO covering Biologics, Drug-device combinations, complex Injectables and Oral Technologies (soft gelatin capsules) 5 state-of-the-art facilities with approval from major regulatory agencies, with 54 successful inspections in last 24 months 1,200+ employees with 100+
Slide 12: Multi-modality approach with a comprehensive suite of services
OneSource stands out among global CDMOs by offering a diverse, multi-modality approach with a comprehensive suite of services Drug-device Combinations Biologics Soft gelatin Sterile fill-finish including GLP-1s (DS and DP) capsules1 (excluding DDCs) ~14% CAGR: % R: ~9 % CAG R: ~5 CAG R: >20% CDMO Ma
Slide 13: Deep expertise, extensive installed capacity, and proven compliance track record
OneSource's deep expertise in development, extensive installed capacity, and proven compliance track record ensure high-quality, reliable service for our clients Formulation capabilities – 35+ approved ANDAs for Sterile Injectables Scale advantage – Installed capacities and soft gelatin capsules acr
Slide 14: Poised for sustained growth driven by industry opportunities and M&A trends
Poised for sustained growth over the coming decades, driven by conducive industry opportunities and M&A trends M&A in CDMO space GLP-1s rise Supply Chain diversification Acquisition of a large CDMO Obesity and Diabetes are major societal challenges à Global biopharmaceuticals looking for alternative
Slide 15: Get in touch with us
the new way to CDMO Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd investor-relations@onesourcecdmo.com Registered Office: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India T: +91 22 2789 2924 F: +91 22 2789 2942 Corporate Office: